

**Supplemental Table 1.** Presumptive diagnoses and outcomes of patients with troponin surge exceeding 1.00 ng/mL

No	Troponin		Cardiac comorbidities				Other comorbidities		Neurological factors		Consensus decision for a possible etiology
	Baseline	Days 2 Days 5	AF	IHD (WMIS)	MH (VMI)	HF (EF)	RI (GFR)	Cancer (D-dimer)	NIHSS score	Insular lesion	
1*	9.86 89.59 36.68	Y	Y (1.7)*	N (144)*	Y (35)*	Y (47)	N (5.41)	16	Y	STEMI with HF history	
2	0.34 22.23 2.34	Y	Y (1.0)	N (88)	Y (61)	Y (58)	N (3.90)	29	Y	R/O SICMP or NSTEMI with aggravated RI (comatose state)	
3	0.02 12.94 5.61	Y	Y (1.0)	N (94)	Y (58)	Y (53)	Y (27.90)	2	N	Newly diagnosed hepatocellular cell carcinoma with metastasis	
4*	0.23 9.14 5.27	N	Y (1.5)*	Y (97)	N (53)	N (53)	N (0.37)	0	N	STEMI	
5*	0.02 6.89 2.55	N	Y (2.0)*	N (174)*	Y (30)*	N (89)	N (3.60)	10	N	STEMI with history of HF	
6	8.85 6.29 3.47	N	N (1.0)	Y (186)*	Y (61)	N (90)	N (0.48)	5	N	Marked sinus bradycardia due to multiple sinus pause	
7	5.18 5.88 2.83	Y	N (1.0)	N (92)	N (56)	N (66)	Y (35.20)	5	N	Newly diagnosed cholangiocarcinoma with metastasis	
8 <sup>†</sup>	0.76 5.84 1.28	Y	Y (1.0)	Y (116)*	N (52)	N (80)	N (0.90)	13	Y	NSTEMI	
9 <sup>†</sup>	0.36 4.98 2.32	N	Y (1.0)	N (77)	Y (66)	Y (8)	N (1.00)	23	Y	NSTEMI with septic shock and aggravated RI	
10	2.68 4.88 1.33	Y	Y (1.0)	N (121)*	Y (58)	Y (11)	N (2.13)	15	Y	Recent UA with end-stage RI	
11	10.60 4.67 1.42	Y	N (1.2)*	Y (149)*	Y (60)	N (60)	N (13.08)	17	N	Infective endocarditis	
12	3.24 4.08 6.01	N	N (1.3)*	Y (100)*	N (64)	Y (38)	N (1.28)	5	N	Other medical conditions (anemia and end-stage RI)	
13	4.39 3.68 1.25	N	Y (1.0)	N (69)*	N (64)	Y (53)	Y (6.22)	6	Y	Newly diagnosed non-small cell lung cancer with metastasis	
14	5.05 2.80 0.56	Y	Y (1.0)	N (121)*	N (60)	Y (59)	N (0.71)	1	N	Pulmonary hypertension due to left ventricular outflow tract obstruction	
15	15.42 2.42 1.01	Y	N (2.0)*	N (57)	Y (45)*	N (84)	N (0.49)	11	Y	SICMP with apical ballooning	
16	0.006 2.11 2.11	N	Y (1.0)	N (105)	Y (64)	N (60)	N (0.45)	2	N	Recent UA with 3-vessel coronary artery disease	
17	0.03 1.50 0.06	N	Y (2.0)*	N (107)	N (36)*	N (80)	N (0.45)	22	Y	R/O SICMP with HF history (comatose state)	

Supplemental Table 1. Continued

No	Troponin		Cardiac comorbidities				Other comorbidities		Neurological factors		Consensus decision for a possible etiology
	Baseline	Days 2 Days 5	AF	IHD (WMIS)	MH (VMI)	HF (EF)	RI (GFR)	Cancer (D-dimer)	NIHSS score	Insular lesion	
18	0.22 1.43 0.24	Y	Y (1.4) <sup>‡</sup>	N (66)	Y (62)	N (75)	N (44.10)	18	Y	R/O SICMP and AF with SVR (comatose state)	
19	1.23 1.31 N/A	N	Y (1.6) <sup>‡</sup>	N (102) <sup>‡</sup>	Y (44) <sup>‡</sup>	Y (29)	Y (30.36)	15	N	Pancreatic cancer with metastasis and inferior vena cava thrombosis	
20	1.10 1.24 0.14	N	N (1.0)	N (85)	N (62)	Y (58)	Y (27.80)	7	N	Cholangiocarcinoma with metastasis and DVT	
21	0.01 1.21 N/A	Y	N (N/A)	Y (N/A)	N (N/A)	Y (58)	N (4.15)	17	N	R/O SICMP and AF with RVR (comatose state due to brainstem infarction)	
22	0.01 1.20 0.006	N	N (1.0)	Y (116) <sup>‡</sup>	N (58)	N (90)	N (0.34)	13	Y	R/O SICMP (neurological deterioration leading to craniectomy)	
23	5.83 0.92 0.48	Y	Y (1.0)	N (131) <sup>‡</sup>	N (61)	N (79)	N (2.88)	13	Y	R/O SICMP (neurological deterioration leading to craniectomy)	
24	1.85 0.82 0.34	Y	N (1.0)	N (108) <sup>‡</sup>	Y (59)	N (62)	N (4.10)	3	Y	AF with SVR	
25	1.54 0.68 0.16	N	Y (1.0)	N (75)	N (67)	N (64)	N (0.37)	0	N	Other medical conditions (polycythemia vera with hyperkalemia)	
26	1.47 0.62 N/A	N	N (1.0)	N (70) <sup>‡</sup>	N (61)	N (82)	Y (24.09)	8	Y	Non-small cell lung cancer with metastasis and DVT	
27	1.03 0.57 N/A	N	N (1.0)	Y (132) <sup>‡</sup>	N (60)	N (75)	N (0.70)	3	N	New-onset UA with 3-vessel coronary artery disease	
28*	0.11 0.36 4.26	N	Y (2.6) <sup>‡</sup>	N (113) <sup>‡</sup>	Y (34) <sup>‡</sup>	Y (4)	Y (35.20)	11	N	Delayed onset STEMI with end-stage RI and renal cell carcinoma	
29	0.03 0.03 4.32	Y	N (1.0)	Y (97) <sup>‡</sup>	N (58)	N (66)	N (0.53)	13	N	AF with RVR	

AF, atrial fibrillation; IHD, ischemic heart disease; WMIS, wall motion index score; MH, myocardial hypertrophy; VMI, ventricular mass index (g/m<sup>2</sup>); HF, heart failure; EF, ejection fraction (%); RI, renal impairment; GFR, glomerular filtration rate (mL/min/1.73 m<sup>2</sup>); NIHSS, National Institutes of Health Stroke Scale; STEMI, ST-segment elevation myocardial infarction; R/O, rule out; SICMP, stress-induced cardiomyopathy; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina; SVR, slow ventricular response; DVT, deep vein thrombosis; RVR, rapid ventricular response; ECG, electrocardiography; LBBB, left bundle branch block; CAD, coronary arterial disease.

\*ECG pattern suspicious of STEMI, which initially developed as an acute ischemic change (e.g., ST-segment elevation or LBBB), followed by newly developed Q-wave on serial ECG investigation; <sup>‡</sup>ECG pattern suspicious of NSTEMI, which transiently/persistently developed as an acute ischemic change (e.g., ST-segment depression with or without T-wave inversion) on serial ECG investigation; <sup>‡</sup>Echocardiographic abnormalities including (1) WMIS (>1 using a standard 16-segment model) compatible with CAD, (2) VMI (>95 g/m<sup>2</sup> for women and >115 g/m<sup>2</sup> for men), and (3) reduced EF (defined as <50%).